CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
Identifieur interne : 004726 ( PascalFrancis/Checkpoint ); précédent : 004725; suivant : 004727CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
Auteurs : Robert Marcus [Royaume-Uni, Canada, Espagne, Australie, France, Belgique, Pologne, Portugal] ; Kevin Imrie ; Andrew Belch ; David Cunningham ; Eduardo Flores ; John Catalano ; Philippe Solal-Celigny ; Fritz Offner ; Jan Walewski ; Jo O Raposo ; Andrew Jack ; Paul SmithSource :
- Blood [ 0006-4971 ] ; 2005.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
The combination of cyclophosphamide, vincristine, and prednisone (CVP) is one of several standard treatment options for advanced follicular lymphoma. This, like similar chemotherapeutic regimens, induces response rates of 60% to 80%, with a median response duration of under 2 years. Rituximab, a chimeric monoclonal antibody against CD20, is active in follicular lymphoma, both as monotherapy and in combination with chemotherapy. Previously untreated patients with stages III to IV follicular lymphoma were randomly assigned to receive either 8 cycles of CVP plus rituximab (R-CVP; n = 162) or CVP (n = 159). Overall and complete response rates were 81% and 41% in the R-CVP arm versus 57% and 10% in the CVP arm, respectively (P <.0001). At a median follow-up of 30 months, patients treated with R-CVP had a very significantly prolonged time to progression (median 32 months versus 15 months for CVP; P <.0001). Median time to treatment failure was 27 months in patients receiving R-CVP and 7 months In the CVP arm (P <.0001). Rituximab did not add significantly to the toxicity of CVP. The addition of rituximab to the CVP regimen significantly improves the clinical outcome in patients with previously untreated advanced follicular lymphoma, without increased toxicity.
Affiliations:
- Australie, Belgique, Canada, Espagne, France, Pologne, Portugal, Royaume-Uni
- Angleterre, Communauté de Madrid, Grand Londres, Pays de la Loire
- Le Mans, Londres, Madrid
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:05-0446726Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma</title><author><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Addenbrooke's Hospital</s1><s2>Cambridge</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Addenbrooke's Hospital</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Toronto-Sunnybrook Regional Cancer Center</s1><s2>Toronto, ON</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Toronto-Sunnybrook Regional Cancer Center</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Cross Cancer Institute</s1><s2>Edmonton, AB</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Cross Cancer Institute</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Royal Marsden Hospital</s1><s2>Surrey</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Royal Marsden Hospital</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Hospital Qregorio Marañón</s1><s2>Madrid</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Monash Medical Centre</s1><s2>Clayton</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Monash Medical Centre</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Clinique Victor Hugo</s1><s2>Le Mans</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Le Mans</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Dienst Hematologie</s1><s2>UZ Gent</s2><s3>BEL</s3></inist:fA14><country>Belgique</country><wicri:noRegion>Dienst Hematologie</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>M. Sklodowska- Curie Memorial Institute</s1><s2>Warszawa</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>M. Sklodowska- Curie Memorial Institute</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Hospital Santa Maria</s1><s2>Usboa</s2><s3>PRT</s3></inist:fA14><country>Portugal</country><wicri:noRegion>Hospital Santa Maria</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Leeds General Infirmary</s1><s2>Leeds</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Leeds General Infirmary</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Cancer Research UK and University College London (UCL) Cancer Trials Centre</s1><s2>London</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Imrie, Kevin" sort="Imrie, Kevin" uniqKey="Imrie K" first="Kevin" last="Imrie">Kevin Imrie</name></author><author><name sortKey="Belch, Andrew" sort="Belch, Andrew" uniqKey="Belch A" first="Andrew" last="Belch">Andrew Belch</name></author><author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name></author><author><name sortKey="Flores, Eduardo" sort="Flores, Eduardo" uniqKey="Flores E" first="Eduardo" last="Flores">Eduardo Flores</name></author><author><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name></author><author><name sortKey="Solal Celigny, Philippe" sort="Solal Celigny, Philippe" uniqKey="Solal Celigny P" first="Philippe" last="Solal-Celigny">Philippe Solal-Celigny</name></author><author><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name></author><author><name sortKey="Walewski, Jan" sort="Walewski, Jan" uniqKey="Walewski J" first="Jan" last="Walewski">Jan Walewski</name></author><author><name sortKey="Raposo, Jo O" sort="Raposo, Jo O" uniqKey="Raposo J" first="Jo O" last="Raposo">Jo O Raposo</name></author><author><name sortKey="Jack, Andrew" sort="Jack, Andrew" uniqKey="Jack A" first="Andrew" last="Jack">Andrew Jack</name></author><author><name sortKey="Smith, Paul" sort="Smith, Paul" uniqKey="Smith P" first="Paul" last="Smith">Paul Smith</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0446726</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0446726 INIST</idno><idno type="RBID">Pascal:05-0446726</idno><idno type="wicri:Area/PascalFrancis/Corpus">004729</idno><idno type="wicri:Area/PascalFrancis/Curation">001974</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">004726</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004726</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma</title><author><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Addenbrooke's Hospital</s1><s2>Cambridge</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Addenbrooke's Hospital</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Toronto-Sunnybrook Regional Cancer Center</s1><s2>Toronto, ON</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Toronto-Sunnybrook Regional Cancer Center</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Cross Cancer Institute</s1><s2>Edmonton, AB</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Cross Cancer Institute</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Royal Marsden Hospital</s1><s2>Surrey</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Royal Marsden Hospital</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Hospital Qregorio Marañón</s1><s2>Madrid</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Monash Medical Centre</s1><s2>Clayton</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Monash Medical Centre</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Clinique Victor Hugo</s1><s2>Le Mans</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Le Mans</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Dienst Hematologie</s1><s2>UZ Gent</s2><s3>BEL</s3></inist:fA14><country>Belgique</country><wicri:noRegion>Dienst Hematologie</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>M. Sklodowska- Curie Memorial Institute</s1><s2>Warszawa</s2><s3>POL</s3></inist:fA14><country>Pologne</country><wicri:noRegion>M. Sklodowska- Curie Memorial Institute</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Hospital Santa Maria</s1><s2>Usboa</s2><s3>PRT</s3></inist:fA14><country>Portugal</country><wicri:noRegion>Hospital Santa Maria</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Leeds General Infirmary</s1><s2>Leeds</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Leeds General Infirmary</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>Cancer Research UK and University College London (UCL) Cancer Trials Centre</s1><s2>London</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Imrie, Kevin" sort="Imrie, Kevin" uniqKey="Imrie K" first="Kevin" last="Imrie">Kevin Imrie</name></author><author><name sortKey="Belch, Andrew" sort="Belch, Andrew" uniqKey="Belch A" first="Andrew" last="Belch">Andrew Belch</name></author><author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name></author><author><name sortKey="Flores, Eduardo" sort="Flores, Eduardo" uniqKey="Flores E" first="Eduardo" last="Flores">Eduardo Flores</name></author><author><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name></author><author><name sortKey="Solal Celigny, Philippe" sort="Solal Celigny, Philippe" uniqKey="Solal Celigny P" first="Philippe" last="Solal-Celigny">Philippe Solal-Celigny</name></author><author><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name></author><author><name sortKey="Walewski, Jan" sort="Walewski, Jan" uniqKey="Walewski J" first="Jan" last="Walewski">Jan Walewski</name></author><author><name sortKey="Raposo, Jo O" sort="Raposo, Jo O" uniqKey="Raposo J" first="Jo O" last="Raposo">Jo O Raposo</name></author><author><name sortKey="Jack, Andrew" sort="Jack, Andrew" uniqKey="Jack A" first="Andrew" last="Jack">Andrew Jack</name></author><author><name sortKey="Smith, Paul" sort="Smith, Paul" uniqKey="Smith P" first="Paul" last="Smith">Paul Smith</name></author></analytic><series><title level="j" type="main">Blood</title><title level="j" type="abbreviated">Blood</title><idno type="ISSN">0006-4971</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Blood</title><title level="j" type="abbreviated">Blood</title><idno type="ISSN">0006-4971</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term><term>Antineoplastic agent</term><term>Chemotherapy</term><term>Cyclophosphamide</term><term>Drug combination</term><term>First line treatment</term><term>Follicular lymphoma</term><term>Human</term><term>Immunotherapy</term><term>Monoclonal antibody</term><term>Prednisone</term><term>Rituximab</term><term>Therapeutic protocol</term><term>Treatment</term><term>Vincristine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Chimiothérapie</term><term>Anticancéreux</term><term>Anticorps monoclonal</term><term>Rituximab</term><term>Stade avancé</term><term>Vincristine</term><term>Immunothérapie</term><term>Prednisone</term><term>Association médicamenteuse</term><term>Lymphome folliculaire</term><term>Protocole thérapeutique</term><term>Traitement</term><term>Cyclophosphamide</term><term>Homme</term><term>Antigène CD20</term><term>Traitement première intention</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The combination of cyclophosphamide, vincristine, and prednisone (CVP) is one of several standard treatment options for advanced follicular lymphoma. This, like similar chemotherapeutic regimens, induces response rates of 60% to 80%, with a median response duration of under 2 years. Rituximab, a chimeric monoclonal antibody against CD20, is active in follicular lymphoma, both as monotherapy and in combination with chemotherapy. Previously untreated patients with stages III to IV follicular lymphoma were randomly assigned to receive either 8 cycles of CVP plus rituximab (R-CVP; n = 162) or CVP (n = 159). Overall and complete response rates were 81% and 41% in the R-CVP arm versus 57% and 10% in the CVP arm, respectively (P <.0001). At a median follow-up of 30 months, patients treated with R-CVP had a very significantly prolonged time to progression (median 32 months versus 15 months for CVP; P <.0001). Median time to treatment failure was 27 months in patients receiving R-CVP and 7 months In the CVP arm (P <.0001). Rituximab did not add significantly to the toxicity of CVP. The addition of rituximab to the CVP regimen significantly improves the clinical outcome in patients with previously untreated advanced follicular lymphoma, without increased toxicity.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-4971</s0></fA01><fA03 i2="1"><s0>Blood</s0></fA03><fA05><s2>105</s2></fA05><fA06><s2>4</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma</s1></fA08><fA11 i1="01" i2="1"><s1>MARCUS (Robert)</s1></fA11><fA11 i1="02" i2="1"><s1>IMRIE (Kevin)</s1></fA11><fA11 i1="03" i2="1"><s1>BELCH (Andrew)</s1></fA11><fA11 i1="04" i2="1"><s1>CUNNINGHAM (David)</s1></fA11><fA11 i1="05" i2="1"><s1>FLORES (Eduardo)</s1></fA11><fA11 i1="06" i2="1"><s1>CATALANO (John)</s1></fA11><fA11 i1="07" i2="1"><s1>SOLAL-CELIGNY (Philippe)</s1></fA11><fA11 i1="08" i2="1"><s1>OFFNER (Fritz)</s1></fA11><fA11 i1="09" i2="1"><s1>WALEWSKI (Jan)</s1></fA11><fA11 i1="10" i2="1"><s1>RAPOSO (Joäo)</s1></fA11><fA11 i1="11" i2="1"><s1>JACK (Andrew)</s1></fA11><fA11 i1="12" i2="1"><s1>SMITH (Paul)</s1></fA11><fA14 i1="01"><s1>Addenbrooke's Hospital</s1><s2>Cambridge</s2><s3>GBR</s3></fA14><fA14 i1="02"><s1>Toronto-Sunnybrook Regional Cancer Center</s1><s2>Toronto, ON</s2><s3>CAN</s3></fA14><fA14 i1="03"><s1>Cross Cancer Institute</s1><s2>Edmonton, AB</s2><s3>CAN</s3></fA14><fA14 i1="04"><s1>Royal Marsden Hospital</s1><s2>Surrey</s2><s3>GBR</s3></fA14><fA14 i1="05"><s1>Hospital Qregorio Marañón</s1><s2>Madrid</s2><s3>ESP</s3></fA14><fA14 i1="06"><s1>Monash Medical Centre</s1><s2>Clayton</s2><s3>AUS</s3></fA14><fA14 i1="07"><s1>Clinique Victor Hugo</s1><s2>Le Mans</s2><s3>FRA</s3></fA14><fA14 i1="08"><s1>Dienst Hematologie</s1><s2>UZ Gent</s2><s3>BEL</s3></fA14><fA14 i1="09"><s1>M. Sklodowska- Curie Memorial Institute</s1><s2>Warszawa</s2><s3>POL</s3></fA14><fA14 i1="10"><s1>Hospital Santa Maria</s1><s2>Usboa</s2><s3>PRT</s3></fA14><fA14 i1="11"><s1>Leeds General Infirmary</s1><s2>Leeds</s2><s3>GBR</s3></fA14><fA14 i1="12"><s1>Cancer Research UK and University College London (UCL) Cancer Trials Centre</s1><s2>London</s2><s3>GBR</s3></fA14><fA20><s1>1417-1423</s1></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>3178</s2><s5>354000132256940050</s5></fA43><fA44><s0>0000</s0><s1>© 2005 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>38 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>05-0446726</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Blood</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>The combination of cyclophosphamide, vincristine, and prednisone (CVP) is one of several standard treatment options for advanced follicular lymphoma. This, like similar chemotherapeutic regimens, induces response rates of 60% to 80%, with a median response duration of under 2 years. Rituximab, a chimeric monoclonal antibody against CD20, is active in follicular lymphoma, both as monotherapy and in combination with chemotherapy. Previously untreated patients with stages III to IV follicular lymphoma were randomly assigned to receive either 8 cycles of CVP plus rituximab (R-CVP; n = 162) or CVP (n = 159). Overall and complete response rates were 81% and 41% in the R-CVP arm versus 57% and 10% in the CVP arm, respectively (P <.0001). At a median follow-up of 30 months, patients treated with R-CVP had a very significantly prolonged time to progression (median 32 months versus 15 months for CVP; P <.0001). Median time to treatment failure was 27 months in patients receiving R-CVP and 7 months In the CVP arm (P <.0001). Rituximab did not add significantly to the toxicity of CVP. The addition of rituximab to the CVP regimen significantly improves the clinical outcome in patients with previously untreated advanced follicular lymphoma, without increased toxicity.</s0></fC01><fC02 i1="01" i2="X"><s0>002B19B</s0></fC02><fC02 i1="02" i2="X"><s0>002B02R02</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Chimiothérapie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Chemotherapy</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Quimioterapia</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Anticancéreux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Antineoplastic agent</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Anticanceroso</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Anticorps monoclonal</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Monoclonal antibody</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Anticuerpo monoclonal</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Rituximab</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Rituximab</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Rituximab</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Stade avancé</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Advanced stage</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Estadio avanzado</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Vincristine</s0><s2>NK</s2><s2>FR</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Vincristine</s0><s2>NK</s2><s2>FR</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Vincristina</s0><s2>NK</s2><s2>FR</s2><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Immunothérapie</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Immunotherapy</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Inmunoterapia</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Prednisone</s0><s2>NK</s2><s2>FR</s2><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Prednisone</s0><s2>NK</s2><s2>FR</s2><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Prednisona</s0><s2>NK</s2><s2>FR</s2><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Association médicamenteuse</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Drug combination</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Asociación medicamentosa</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Lymphome folliculaire</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Follicular lymphoma</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Linfoma folicular</s0><s5>10</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Protocole thérapeutique</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Therapeutic protocol</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Protocolo terapéutico</s0><s5>11</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Traitement</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Treatment</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Tratamiento</s0><s5>12</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Cyclophosphamide</s0><s2>NK</s2><s2>FR</s2><s5>13</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Cyclophosphamide</s0><s2>NK</s2><s2>FR</s2><s5>13</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Ciclofosfamida</s0><s2>NK</s2><s2>FR</s2><s5>13</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Homme</s0><s5>17</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Human</s0><s5>17</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Hombre</s0><s5>17</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Antigène CD20</s0><s4>INC</s4><s5>86</s5></fC03><fC03 i1="16" i2="X" l="FRE"><s0>Traitement première intention</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="16" i2="X" l="ENG"><s0>First line treatment</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="16" i2="X" l="SPA"><s0>Tratamiento primer línea</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Anticytokine</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Anticytokine</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Anticitoquina</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Hémopathie maligne</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Malignant hemopathy</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Hemopatía maligna</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Lymphome non hodgkinien</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Non Hodgkin lymphoma</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Linfoma no Hodgkin</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Lymphoprolifératif syndrome</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0><s5>40</s5></fC07><fN21><s1>311</s1></fN21></pA></standard></inist><affiliations><list><country><li>Australie</li><li>Belgique</li><li>Canada</li><li>Espagne</li><li>France</li><li>Pologne</li><li>Portugal</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Communauté de Madrid</li><li>Grand Londres</li><li>Pays de la Loire</li></region><settlement><li>Le Mans</li><li>Londres</li><li>Madrid</li></settlement></list><tree><noCountry><name sortKey="Belch, Andrew" sort="Belch, Andrew" uniqKey="Belch A" first="Andrew" last="Belch">Andrew Belch</name><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name><name sortKey="Flores, Eduardo" sort="Flores, Eduardo" uniqKey="Flores E" first="Eduardo" last="Flores">Eduardo Flores</name><name sortKey="Imrie, Kevin" sort="Imrie, Kevin" uniqKey="Imrie K" first="Kevin" last="Imrie">Kevin Imrie</name><name sortKey="Jack, Andrew" sort="Jack, Andrew" uniqKey="Jack A" first="Andrew" last="Jack">Andrew Jack</name><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name><name sortKey="Raposo, Jo O" sort="Raposo, Jo O" uniqKey="Raposo J" first="Jo O" last="Raposo">Jo O Raposo</name><name sortKey="Smith, Paul" sort="Smith, Paul" uniqKey="Smith P" first="Paul" last="Smith">Paul Smith</name><name sortKey="Solal Celigny, Philippe" sort="Solal Celigny, Philippe" uniqKey="Solal Celigny P" first="Philippe" last="Solal-Celigny">Philippe Solal-Celigny</name><name sortKey="Walewski, Jan" sort="Walewski, Jan" uniqKey="Walewski J" first="Jan" last="Walewski">Jan Walewski</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name></noRegion><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name></country><country name="Canada"><noRegion><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name></noRegion><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name></region></country><country name="Australie"><noRegion><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name></noRegion></country><country name="France"><region name="Pays de la Loire"><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name></region></country><country name="Belgique"><noRegion><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name></noRegion></country><country name="Pologne"><noRegion><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name></noRegion></country><country name="Portugal"><noRegion><name sortKey="Marcus, Robert" sort="Marcus, Robert" uniqKey="Marcus R" first="Robert" last="Marcus">Robert Marcus</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004726 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 004726 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:05-0446726
|texte= CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
}}
| This area was generated with Dilib version V0.6.33. |  |